No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Nonobstructive HCM is a much more complex and heterogeneous population than obstructive HCM. We need to understand nonobstructive HCM better and determine whether there are subgroups that do benefit from cardiac myosin inhibitors.”
Phase 3 trial assessed mavacamten's effects on peak oxygen uptake and health status in nonobstructive HCM, suggesting limited improvement.
Desai et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: